Compare CAVA Group Inc (CAVA) vs Johnson & Johnson (JNJ) Price & Performance

CAVA Group (CAVA) is trading at $69.47, up 12.81% following strong Q2 2026 earnings that beat estimates with $0.19 EPS and 31.3% revenue growth. The stock shows bearish technical signals despite recent momentum, with key resistance at $62-64. Fundamentally, CAVA maintains robust revenue expansion and profitability with 24.69% gross margins, though valuation multiples remain elevated at P/E of 108.59.

The outlook remains positive given analyst consensus of 19 buys and $89.75 price target, representing 29% upside potential. Key risks include high valuation sensitivity, competitive pressures in fast-casual dining, and execution challenges in restaurant expansion. Recent same-store sales growth of 9% supports continued momentum if operational excellence persists.

Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.

Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.